<DOC>
	<DOCNO>NCT00696111</DOCNO>
	<brief_summary>The purpose study look metabolic ( use energy ) hormonal feature sleep problem woman polycystic ovary syndrome ( PCOS ) .</brief_summary>
	<brief_title>Metabolic Study Women With Polycystic Ovary Syndrome Sleep Apnea</brief_title>
	<detailed_description>The prevalence obesity chronic sleep loss record level among Americans evidence continue emerge support causal link two condition . Metabolic abnormality relate sleep disruption particularly evident individual obstructive sleep apnea ( OSA ) , disorder traditionally associate male gender . While prevalent men , OSA underrecognized woman part clinical polysomnographic feature differ men . Women polycystic ovary syndrome ( PCOS ) particularly susceptible OSA least 5-fold high risk development compare obese woman without PCOS . This study enroll obese woman PCOS , without OSA . Those OSA randomize receive CPAP receive depot leuprolide suppress ovarian steroid output 12 week , reassess 6 week , randomize ( double-blind , placebo control ) 6 week either micronized estrogen + placebo micronized progestin + placebo . The independent effect androgen , estrogen , progesterone OSA metabolic function assess . In addition , primary human adipocytes prepare fat biopsy obtain subject . Insulin sensitivity determine phospho-specific immunoblotting conjunction glucose uptake anti-lipolysis assay . In parallel , adipocytes subject culture 1-5 day prior metabolic assay ascertain removal circulating factor improve insulin signaling , insulin resistance persist vitro . Finally , interface Metabolomics Laboratory Duke University ( C. Newgard , Lab Director ) , metabolomics assessment do blood urine sample .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Apnea</mesh_term>
	<mesh_term>Sleep Apnea Syndromes</mesh_term>
	<mesh_term>Sleep Apnea , Obstructive</mesh_term>
	<mesh_term>Polycystic Ovary Syndrome</mesh_term>
	<mesh_term>Leuprolide</mesh_term>
	<mesh_term>Progesterone</mesh_term>
	<mesh_term>Estrogens</mesh_term>
	<criteria>Clinical diagnosis PCOS Obese ( BMI least 30 kg/m2 ) Diagnosis nonclassic 21hydroxylase deficiency , Cushing syndrome , hypothyroidism , significant elevation prolactin Taking steroid preparation ( include oral contraceptive ) , medication know alter insulin secretion and/or action , medication know influence sleep 2 month prior start study Positive pregnancy test Diagnosis diabetes mellitus Hypertension ( systolic &gt; 140 mmHg and/or diastolic &gt; 90 mmhg ) wellcontrolled stable medication either ACE inhibitor diuretics Habitual alcohol use Excessive caffeine intake 300 mg/day Known peanut allergy , allergy medication use study Hemoglobin &lt; 11g/dL and/or hematocrit &lt; 33 % Systemic illness , include heart , renal , liver , malignant disease</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>PCOS</keyword>
	<keyword>OSA</keyword>
	<keyword>Metabolism</keyword>
	<keyword>Diabetes</keyword>
</DOC>